US PMAs Are The New Reality For Metal-On-Metal Hips
This article was originally published in SRA
Executive Summary
Manufacturers have until May 18 to either submit a premarket approval application (PMA) for their metal-on-metal (MoM) hip products or take them off the market, the US Food and Drug Administration announced in a Feb. 18 final order1.
You may also be interested in...
FDA Advisory Panel Debates Science On Human Adverse Biological Reactions To Metal-Containing Devices
US FDA scientists and immunological experts discussed the latest science regarding patients’ biological reactions to metal implants and mercury in dental amalgam at a 13-14 November agency advisory committee meeting. The get-together was held to determine what additional actions the FDA can take to make sure certain patients are protected from immunological risks of the implants. The panel ultimately backed a transition away from mercury amalgam dental fillings and pushed for more research into risks associated with metal implants.
Market Intel: Market Dynamics Switchover To Come In Fast-Growing Soft Tissue Fixation Segment
Global sales for arthroscopy and sports medicine devices are predicted to hit $6.5bn by 2021. This will be driven by the fast-growing soft tissue fixation products segment: significant changes in market dynamics are expected over the next few years, as hip fixation procedures pick up pace. This article delves into the landscape of the soft tissue fixation device market, as well as the four key segments in the arthroscopy devices space. It will also analyze the key players in these markets, highlight trends and discuss the biggest challenges.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.